NCT02739217View on ClinicalTrials.gov

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

September 26, 2017

Study Completion Date

June 4, 2018

Conditions
Inflammation and FibrosisDiabetes
Interventions
DRUG

PBI-4050

Four 200 mg capsules (800 mg total) administered orally, once daily.

Trial Locations (1)

B15 2PR

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY

NCT02739217 - Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome | Biotech Hunter | Biotech Hunter